Business · 19/07/2021

FDA Releases Draft Guidance for Cilastatin Sodium; Imipenem; Relebactam

The US Food and Drug Administration (FDA) has released a draft guidance document for the pharmaceutical industry, outlining product-specific recommendations for the development of cilastatin sodium; imipenem; relebactam for injection, including bioequivalence studies to support abbreviated new drug applications (ANDAs).